Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1600 1611 1615 1625 1627 1699 3649
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18001075 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION | Non-Final OA | ETH ZÜRICH |
| 18488191 | COMPOUND FOR THE TREATMENT OF CANCER | Non-Final OA | Pfizer Inc. |
| 17786187 | NEW THERAPY | Final Rejection | UCL Business Ltd |
| 17230270 | METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS | Final Rejection | Opus Genetics, Inc. |
| 18014032 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | Final Rejection | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL |
| 17920019 | 6'-METHOXYCINCHONAN-9-OLS FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | Final Rejection | Immunologik GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy